Fresenius Medical Care (NYSE:FMS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note issued to investors on Tuesday. The brokerage issued a strong-buy rating on the stock.

A number of other brokerages also recently commented on FMS. Truist Financial increased their price target on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the company a “hold” rating in a report on Monday, May 12th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care in a report on Thursday, May 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $27.80.

Fresenius Medical Care Trading Up 2.5%

Shares of Fresenius Medical Care stock opened at $29.88 on Tuesday. The company has a market capitalization of $17.53 billion, a P/E ratio of 24.69, a P/E/G ratio of 0.76 and a beta of 0.85. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The company has a fifty day moving average of $25.22 and a 200 day moving average of $23.84. Fresenius Medical Care has a fifty-two week low of $17.93 and a fifty-two week high of $30.29.

Fresenius Medical Care (NYSE:FMS) last posted its earnings results on Tuesday, May 6th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.01. The company had revenue of $5.54 billion for the quarter, compared to the consensus estimate of $4.71 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. On average, sell-side analysts anticipate that Fresenius Medical Care will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be issued a dividend of $0.7871 per share. This represents a yield of 1.9%. This is a positive change from Fresenius Medical Care’s previous annual dividend of $0.44. The ex-dividend date of this dividend is Friday, May 23rd. Fresenius Medical Care’s dividend payout ratio (DPR) is presently 49.11%.

Institutional Investors Weigh In On Fresenius Medical Care

Several institutional investors have recently bought and sold shares of the company. Pzena Investment Management LLC boosted its stake in Fresenius Medical Care by 0.6% in the first quarter. Pzena Investment Management LLC now owns 15,377,090 shares of the company’s stock valued at $382,890,000 after acquiring an additional 94,065 shares in the last quarter. Millennium Management LLC boosted its stake in Fresenius Medical Care by 50.0% in the first quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock valued at $26,982,000 after acquiring an additional 361,364 shares in the last quarter. Integral Health Asset Management LLC boosted its stake in Fresenius Medical Care by 33.3% in the fourth quarter. Integral Health Asset Management LLC now owns 600,000 shares of the company’s stock valued at $13,584,000 after acquiring an additional 150,000 shares in the last quarter. Todd Asset Management LLC acquired a new stake in Fresenius Medical Care in the first quarter valued at approximately $12,009,000. Finally, Northern Trust Corp boosted its stake in Fresenius Medical Care by 5.0% in the first quarter. Northern Trust Corp now owns 380,251 shares of the company’s stock valued at $9,468,000 after acquiring an additional 18,061 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.